Safety and effectiveness of fosravuconazole for the treatment of onychomycosis in haemodialysis patients: A single‐centre retrospective study
Abstract
The prevalence of onychomycosis is higher in haemodialysis patients than in the general population. 1 Fosravuconazole, a novel oral triazole antifungal agent, showed efficacy and tolerable safety for the treatment of onychomycosis in a clinical trial. 2 However, haemodialysis patients were excluded from the clinical trial due to safety concerns. We investigated the safety and effectiveness of fosravuconazole for onychomycosis in haemodialysis patients
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.